These 10 Firms Were Last Week’s Worst Performers

6. Neurocrine Biosciences Inc. (NASDAQ:NBIX)

Shares of Neurocrine plummeted 19 percent week-on-week to close Friday’s trading at $122.62 each as investors digested its lackluster fourth-quarter earnings performance and conservative outlook guidance for 2025.

In its earnings release last week, NBIX said net income in the last quarter fell by 30 percent to $103.1 million from the $147.7 million reported in the same period last year, despite revenues increasing by 21.8 percent to $627.7 million from $515.2 million.

Revenues for the full year increased by 24.8 percent to $2.355 billion from $1.887 billion, pushing net income higher by 36.68 percent at $341.3 million versus the $249.7 million registered in 2023.

For this year, NBIX merely reported a conservative outlook, saying full-year net product sales are projected to settle between $2.5 billion and $2.6 billion.

“With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company,” said NBIX CEO Kyle Gano.